Search Results
Your search for The A,The A matches 33571 pages
Showing 30351 - 30400Expert Point of View: Susan M. O’Brien, MD
Until recently, chlorambucil (Leukeran) was the standard of care for older patients with chronic lymphocytic leukemia (CLL) in Europe. In several studies, chlorambucil combined with newer drugs—for example, anti-CD20 antibodies, obinutuzumab (Gazyva), or ofatumumab (Arzerra)—improved survival,...
Ibrutinib Bests Standard of Care for Elderly Patients With CLL
First-line treatment with the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) significantly reduced the risk of dying or disease progression compared with chlorambucil (Leukeran) in older treatment-naive patients with chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial. At the time...
Expert Point of View: Virginia Kaklamani, MD
Press conference moderator Virginia Kaklamani, MD, commented on these results from the ABCSG-18 trial: “It’s pretty clear that 3 years of adjuvant denosumab not only reduced fracture risk but improved disease-free survival. It’s also pretty clear that adjuvant bisphosphonates improve disease-free...
Adjuvant Denosumab Improves Disease-Free Survival in Estrogen Receptor–Positive Postmenopausal Breast Cancer
There is good news about denosumab (Prolia). The primary analysis of the ABCSG-18 trial showed that adjuvant denosumab (given at low doses) reduces the risk of clinical fracture by 50% in postmenopausal women with early breast cancer who are taking an aromatase inhibitor.1 More good news is that...
Patients With Incomplete Response to Neoadjuvant Chemotherapy Benefit From Capecitabine
Treatment with capecitabine increased disease-free and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy, according to a study reported by researchers from Japan and Korea at the 2015 San Antonio Breast Cancer Symposium.1 “It has been unclear whether...
A Shot to End Cancer: HPV Vaccination
As health-care providers, we have an obligation and a responsibility not only to care for our patients, but also to educate them—and the general public—about their cancer risk and ways to reduce or prevent it. We are living in the golden era of cancer prevention and treatment, made possible by...
Expert Point of View: Sagar Lonial, MD
At an educational session at the 2015 American Society of Hematology Annual Meeting and Exposition, Sagar Lonial, MD, of Emory University, Atlanta, elaborated upon this topic. The pooled analysis of daratumumab (Darzalex) monotherapy, he said, “demonstrated significant activity and, not only this,...
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma
The anti-CD38 monoclonal antibody daratumumab (Darzalex) took center stage among multiple myeloma studies presented at the 57th American Society of Hematology Annual Meeting and Exposition. In relapsed/refractory patients, daratumumab plus lenalidomide (Revlimid)/dexamethasone yielded an 81%...
New Study Suggests Benefits of Regular Mammography Extend to the Elderly
Breast cancer afflicts 1 in 8 women in their lifetime, and 1 in 25 die from this disease. Although a number of randomized trials have demonstrated the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over age 74, especially among...
American Psychosocial Oncology Society Endorses Psychosocial Standards of Care for Children With Cancer and Their Families
The American Psychosocial Oncology Society (APOS) has endorsed the “Psychosocial Standards of Care for Children with Cancer and Their Families” published in a December 2015 special supplement to Pediatric Blood and Cancer. The scientific, evidence-based psychosocial standards...
National Cancer Database Study Indicates Racial Differences in Neoadjuvant Chemotherapy Use in Women With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Killelea et al found that chemotherapy, particularly neoadjuvant chemotherapy, was more frequently given to black, Hispanic, and Asian women vs white women with stage I to III breast cancer, with the difference largely attributable to more...
Tumor Tissue Specimens and Associated Analyses Appear to Be a Significant Barrier to Clinical Trial Enrollment
The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment. Potential solutions to reducing or eliminating these barriers include routine tissue banking at...
DNA Repair Enzyme Identified as a Potential Brain Cancer Drug Target
Rapidly dividing cells rely on an enzyme called Dicer to help them repair the DNA damage that occurs as they make mistakes in copying their genetic material over and over for new cells. Researchers have built on the discovery of Dicer’s role in fixing DNA damage to uncover a new potential...
Study Finds Cardiovascular Disease Is Prevalent and Often Asymptomatic in Childhood Cancer Survivors
Although historically the leading cause of death among survivors of childhood cancer has been cancer recurrence, adverse late effects of cancer therapy have become the leading cause of death 30 years after diagnosis, and those deaths are frequently attributed to premature cardiovascular disease,...
Electronic Symptom Self-Reporting During Cancer Treatment May Be Associated With Better Quality of Life and Other Clinical Benefits
As reported in the Journal of Clinical Oncology by Basch et al, a trial conducted among patients receiving routine outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center indicated that patient use of tablet computers to report common symptoms was associated with ...
Gene Thought to Suppress Cancer May Actually Promote Spread of Colorectal Cancer
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri (MU) School of Medicine researchers have found. It is a finding that may lay the foundation for new colorectal cancer treatments. Results ...
Travel Distance Is Still a Barrier to Breast Reconstruction After Mastectomy
Long travel distances continue to be a significant obstacle to breast reconstruction after mastectomy for breast cancer, according to a study published by Abornoz et al in Plastic and Reconstructive Surgery. “While greater patient awareness and insurance coverage have contributed to greater...
Adding Ibrutinib to Bendamustine/Rituximab May Increase Progression-Free Survival in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In the phase III HELIOS trial reported in The Lancet Oncology, Chanan-Khan et al found that the addition of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic ...
Study Reports Improved Survival With Lapatinib and CapeOx in Asian and Younger Patients With HER2-Positive Advanced Gastroesophageal Adenocarcinoma
In a phase III trial (TRIO-013/LOGiC) reported in the Journal of Clinical Oncology, Hecht et al found that the addition of lapatinib (Tykerb) to capecitabine-oxaliplatin (CapeOx) in patients with previously untreated HER2-amplified advanced gastroesophageal adenocarcinoma did not improve overall...
Even Before Affordable Care Act, Cancer Survivors in Nonexpansion States Had Less Health-Care Access
An analysis published by Tarazi et al in the Journal of Cancer Survivorship found that even in the health-care landscape before the Affordable Care Act, cancer survivors in states that had already expanded Medicaid coverage prior to passage of the Act had more access to health care than cancer...
More Than One-Third of Patients With Metastatic Cancer Continue to Work
A new analysis indicated that many patients continue working after being diagnosed with metastatic cancer, but a heavy burden of symptoms may prevent them from doing so. Published by Tevaarwerk et al in Cancer, the study illustrates the need to treat difficult symptoms so that patients can maintain ...
Stereotactic Body Radiotherapy vs Radiofrequency Ablation in Inoperable Nonmetastatic Hepatocellular Carcinoma
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Wahl et al found that stereotactic body radiotherapy may provide better freedom from local tumor progression vs radiofrequency ablation in patients with inoperable nonmetastatic larger hepatocellular...
Patient-Reported Outcomes With Adjuvant Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
As reported in The Lancet and at the recent San Antonio Breast Cancer Symposium, Ganz et al found differences in patient-reported outcomes with anastrozole vs tamoxifen in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial in postmenopausal women with hormone...
Andrew Seidman, MD, and Hope Rugo, MD, on Reducing Alopecia: FDA Approves New Device
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss the recent approval of a cooling cap to reduce hair loss during chemotherapy.
Andrew Seidman, MD, and Seema Khan, MD, MPH on Controversies in the Management of DCIS
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).
Clifford Hudis, MD, and Carlos Arteaga, MD, on Metabolic Syndrome and Obesity in Breast Cancer
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.
Clifford Hudis, MD, and Julia White, MD, on Early-Stage Breast Cancer: Hypofractionated Radiotherapy
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Clifford Hudis, MD, and William Gradishar, MD: Expert Perspective
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and William J. Gradishar, MD, of the Lurie Comprehensive Cancer Center, discuss the most important papers and results at this year's San Antonio Breast Cancer Symposium.
Lisa Carey, MD, and Jay Harris, MD, on Critical Decision Making in Radiation Therapy for Breast Cancer
Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.
Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial
Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on adjuvant CAF plus tamoxifen, vs tamoxifen in postmenopausal patients with estrogen receptor–positive, node-positive breast cancer...
Lisa Carey, MD, and Sibylle Loibl, MD, PhD: Update on Metastatic Disease
Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy, and brain metastases (Abstract YR4).
Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data...
Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).
Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial
Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).
James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial
James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor (Abstract 99).
James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).
S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.
Alok A. Khorana, MD, on Preventing Venous Thromboembolism
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).
Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease
Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).
Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease ...
Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results
Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).
Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Rafat Abonour, MD, of Indiana University Simon Cancer Center, discuss the session that he chaired on the question of whether researchers can design therapy that addresses the heterogeneity of the disease and eradicate most if...
David A. Williams, MD, on the Goals and Highlights of ASH 2015
Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.
Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).
Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).
James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant
James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).
Jonathon Cohen, MD, on Deferring MCL Treatment
Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).
Richard M. Stone, MD, on AML: Results of the RATIFY Trial
Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).
